New product: Cinqaero (reslizumab) 10 mg/mL concentrate for solution for infusion -

New product: Cinqaero (reslizumab) 10 mg/mL concentrate for solution for infusion
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Respiratory disorders
Summary
Reslizumab is licensed as as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
UKMi comment
Reslizumab is a humanised monoclonal antibody to interkeuukin-5. NICE are currently reviewing reslizumab under a technology appraisal, expecting to produce guidance in April 2017.
Related links: NICE TA in Progress